Showing 2,676 results

Filters Content type: News, Editors' picks, About HIV Topic: Hepatitis & HIV

Hepatitis A, B and C are viral infections that can damage the liver and cause serious illnesses. Co-infection with HIV and hepatitis B or C is quite common. Safe and effective treatments are available.

Pharmaceutical industry

Gilead to raise price for new hepatitis C drug above $84000

Editor's pick
Reuters
15 September 2014
Hepatitis C treatment

Simeprevir in hepatitis C: added benefit for certain patients

Editor's pick
German Institute for Quality and Efficiency in Health Care
10 September 2014
Access to healthcare

Gilead close to sending $84,000 drug to poor countries

Editor's pick
Bloomberg
9 September 2014
Hepatitis C treatment

Doctors Battle Insurers for Access to Pricey Hepatitis C Drugs

Editor's pick
Healthline
9 September 2014
Hepatitis C transmission & prevention

HIV-Negative Gay Men May Acquire Hepatitis C Sexually

Editor's pick
Aidsmeds.com
9 September 2014
Hepatitis & HIV

US: HIV medical organizations challenge insurer restrictions to HCV treatment

Editor's pick
EATG / AAHIVM / HIVMA
4 September 2014
Hepatitis C transmission & prevention

That holiday pedicure may leave you with hepatitis C

Editor's pick
Courier Mail
1 September 2014
Hepatitis C treatment

MSF urges BMS to make daclatasvir accessible in low-and middle-income countries

Editor's pick
Pharmabiz
1 September 2014
New & experimental hepatitis C treatment

European Commission Approves Bristol-Myers Squibb’s Daklinza (daclatasvir) Across Multiple Genotypes for the Treatment of Chronic Hepatitis C Infection

Editor's pick
Bristol-Myers Squibb
27 August 2014
Hepatitis B

One out of 10 Asian Americans has hepatitis B

Editor's pick
Philippine Star
27 August 2014
Hepatitis C treatment

The Risky Business of Limiting Medicaid Access to Sovaldi

Editor's pick
Governing
21 August 2014
Hepatitis C treatment

Nearly Half of Surveyed US Specialists Expect to Prescribe Gilead's Sofosbuvir / Ledipasvir Regimen Near-Term for Hepatitis C Infections

Editor's pick
Decision Resources Group press release
21 August 2014
Hepatitis C transmission & prevention

Expanded harm reduction provision achieves impressive reductions in HCV incidence among PWID in Scotland

News
20 August 2014
Hepatitis C treatment

Britain Has No Problem Paying for Expensive Hepatitis C Drugs

Editor's pick
Businessweek
19 August 2014
New & experimental hepatitis C treatment

PegLambda discontinued by BMS

Editor's pick
EATG
18 August 2014
Hepatitis C transmission & prevention

Emergent HCV epidemic among young, non-urban people who inject drugs in the United States

News
18 August 2014
New & experimental hepatitis C treatment

Achillion Achieves 100 Percent Sustained Virologic Response Rate (SVR4) From an Eight Week Phase 2 Trial Evaluating a Ribavirin-Free Regimen of ACH-3102 and Sofosbuvir for Genotype 1 HCV ("Proxy Study")

Editor's pick
Achillion press release
18 August 2014
Hepatitis C treatment

NICE consults on further draft guidance on the drug sofosbuvir (Sovaldi) for treating hepatitis C

Editor's pick
NICE
15 August 2014
Hepatitis C treatment

UK cost body backs pricey Gilead hepatitis pill for some patients

Editor's pick
Reuters
15 August 2014
Hepatitis C treatment

OTP patients, ideal for new hepatitis C medication, put on bottom of list by payers

Editor's pick
Alcohol & Drug Abuse Weekly
14 August 2014
Hepatitis B

Study in Malawi shows importance of screening HIV-positive patients for HBV co-infection and using tenofovir-containing regimens

News
14 August 2014
Hepatitis C treatment

Vertex to stop selling hepatitis C drug Incivek, once a blockbuster, in October

Editor's pick
Boston Business Journal (blog)
13 August 2014
Hepatitis C treatment

Gilead in talks with Indian drugmakers to sell Sovaldi at cut-rate prices

Editor's pick
Fierce Pharma
11 August 2014
Prisoners

Why the Hepatitis Cure Sovaldi Is a Budgetary Disaster for Prisons

Editor's pick
New York Times
7 August 2014